L. Gayani Tillekeratne
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
L. Gayani Tillekeratne has a total of 432 co-authors. Here are the top co-authors by number of shared publications:
- Champica K. Bodinayake
University of Ruhuna
21 shared publications Ajith Nagahawatte
15 shared publications- Christopher W. Woods
Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA
14 shared publications Ruvini Kurukulasooriya
University of Ruhuna
14 shared publicationsChristopher W. Woods
12 shared publications- Truls Østbye
Department of Family Medicine and Community Health, Duke University, Durham, NC, USA
10 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Elsevier in SSRN Electronic Journal
Diagnostic Blind Spots in Leptospirosis: How Serial Testing and Disease Severity Impact Diagnostic Yield in an Endemic Setting of Sri Lanka
Background: Healthcare systems in these low- and middle-income settings remain severely constrained by a reliance on single acute-phase diagnostic testing for leptospirosis. To evaluate the impact of serial diagnostic testing for leptospirosis in an endemic tropical setting on the diagnostic yield and its relationship with the disease severity. Methods: In this prospective observational cohort study, 354 patients meeting the 2013 CDC clinical case definition for suspected leptospirosis were recruited from four hospitals in Southern Sri Lanka (March-September 2024). Quantitative PCR (qPCR) and microscopic agglutination testing(MAT) were performed on acute-phase samples, with repeat testing at discharge and one-month follow-up. Patients were classified using a four-tier framework based on combined qPCR and MAT results.Findings: Of 354 patients, 190(53·7%) were Confirmed, 72(20·3%) Probable, 64(18·1%) Possible, and 28(7·9%) Negative. Confirmed cases increased from 42·4% with acute-phase testing alone to 63·6% after discharge sampling and 74·0% with post-discharge follow-up. Among 63 patients initially negative by both qPCR and MAT who attended follow-up, 32 (50·8%) seroconverted. Among them, 10 (17·5%) were first detected at the discharge sample and 47 (82·4%) required post-discharge follow-up. Of the 93 patients with dual-replicate qPCR positivity, 71 (76·3%) never developed a reactive MAT titre at any timepoint; conversely, 71(37·4%) Confirmed had negative qPCR and were identified by MAT criteria. Severe disease showed lower qPCR positivity (26·5% vs. 67·6%; p<0·001) but higher acute MAT positivity (51·0% vs. 23·5%; p=0·005) than mild disease.Interpretation: Single acute-phase testing substantially underestimates leptospirosis. Serial qPCR and MAT testing significantly improves diagnostic confirmation and supports routine follow-up serology to improve diagnosis and management in endemic settings.
- 1 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessDiagnostic Blind Spots in Leptospirosis: How Serial Testing and Disease Severity Impact Diagnostic Yield in an Endemic Setting of Sri Lanka
Background: Healthcare systems in these low- and middle-income settings remain severely constrained by a reliance on single acute-phase diagnostic testing for leptospirosis. To evaluate the impact of serial diagnostic testing for leptospirosis in an endemic tropical setting on the diagnostic yield and its relationship with the disease severity. Methods: In this prospective observational cohort study, 354 patients meeting the 2013 CDC clinical case definition for suspected leptospirosis were recruited from four hospitals in Southern Sri Lanka (March-September 2024). Quantitative PCR (qPCR) and microscopic agglutination testing(MAT) were performed on acute-phase samples, with repeat testing at discharge and one-month follow-up. Patients were classified using a four-tier framework based on combined qPCR and MAT results.Findings: Of 354 patients, 190(53·7%) were Confirmed, 72(20·3%) Probable, 64(18·1%) Possible, and 28(7·9%) Negative. Confirmed cases increased from 42·4% with acute-phase testing alone to 63·6% after discharge sampling and 74·0% with post-discharge follow-up. Among 63 patients initially negative by both qPCR and MAT who attended follow-up, 32 (50·8%) seroconverted. Among them, 10 (17·5%) were first detected at the discharge sample and 47 (82·4%) required post-discharge follow-up. Of the 93 patients with dual-replicate qPCR positivity, 71 (76·3%) never developed a reactive MAT titre at any timepoint; conversely, 71(37·4%) Confirmed had negative qPCR and were identified by MAT criteria. Severe disease showed lower qPCR positivity (26·5% vs. 67·6%; p<0·001) but higher acute MAT positivity (51·0% vs. 23·5%; p=0·005) than mild disease.Interpretation: Single acute-phase testing substantially underestimates leptospirosis. Serial qPCR and MAT testing significantly improves diagnostic confirmation and supports routine follow-up serology to improve diagnosis and management in endemic settings.
- Open Access
- 28 September 2026
- Published by Elsevier in SSRN Electronic Journal
National Point-Prevalence Study Of Antibacterial Prescription In Public Hospitals In Sri Lanka
Background: Antimicrobial resistance is a global health crisis that is driven by inappropriate antibacterial use. We studied the prevalence, patterns, and indications of antibacterial prescription in public hospitals in Sri Lanka. Methods: Single-day, point-prevalence surveys were conducted among inpatients in medical, surgical, pediatric wards, and intensive-care units (ICU) in 18 public hospitals in six provinces in Sri Lanka in Aug-Nov 2024. One each from tertiary, secondary, and primary-level hospitals were included per province. Data were collected from medical records. Findings: Of 3866 patients, 2327 were from tertiary, 1396 from secondary, and 141 from primary hospitals. Prevalence of antibacterial prescription in tertiary, secondary and primary hospitals was 56·7%, 52·6%, and 49·6%, respectively. The highest antibacterial prescription was in ICUs (92·9%).Among tertiary and secondary hospitals, commonly prescribed antibacterials were amoxicillin-clavulanate (20·4% of total number of antibacterials), third-generation cephalosporins (19·5%), and metronidazole (10·8%). Carbapenem prescription was 7·2% and 4·3% in tertiary and secondary hospitals, respectively and most common in ICUs (18·8%). Prescription of ‘Access’ group antibacterials was 58·3% in tertiary, 65·5% in secondary, and 91·3% in primary while prescription of ‘Reserve’ group was <1% across all facilities. Common indications for antibacterials were cellulitis/abscess/soft tissue infections (28·9%), and lower respiratory tract infections/pneumonia (25·2%). Associated microbiologic cultures were ordered in 37·5% patients in tertiary, 18% in secondary, and 0% in primary hospitals. Interpretation: Improving diagnostic capacity and reducing use of carbapenems were identified as antimicrobial stewardship targets. Funding: Duke Global Health Institute
- 28 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessNational Point-Prevalence Study Of Antibacterial Prescription In Public Hospitals In Sri Lanka
Background: Antimicrobial resistance is a global health crisis that is driven by inappropriate antibacterial use. We studied the prevalence, patterns, and indications of antibacterial prescription in public hospitals in Sri Lanka. Methods: Single-day, point-prevalence surveys were conducted among inpatients in medical, surgical, pediatric wards, and intensive-care units (ICU) in 18 public hospitals in six provinces in Sri Lanka in Aug-Nov 2024. One each from tertiary, secondary, and primary-level hospitals were included per province. Data were collected from medical records. Findings: Of 3866 patients, 2327 were from tertiary, 1396 from secondary, and 141 from primary hospitals. Prevalence of antibacterial prescription in tertiary, secondary and primary hospitals was 56·7%, 52·6%, and 49·6%, respectively. The highest antibacterial prescription was in ICUs (92·9%).Among tertiary and secondary hospitals, commonly prescribed antibacterials were amoxicillin-clavulanate (20·4% of total number of antibacterials), third-generation cephalosporins (19·5%), and metronidazole (10·8%). Carbapenem prescription was 7·2% and 4·3% in tertiary and secondary hospitals, respectively and most common in ICUs (18·8%). Prescription of ‘Access’ group antibacterials was 58·3% in tertiary, 65·5% in secondary, and 91·3% in primary while prescription of ‘Reserve’ group was <1% across all facilities. Common indications for antibacterials were cellulitis/abscess/soft tissue infections (28·9%), and lower respiratory tract infections/pneumonia (25·2%). Associated microbiologic cultures were ordered in 37·5% patients in tertiary, 18% in secondary, and 0% in primary hospitals. Interpretation: Improving diagnostic capacity and reducing use of carbapenems were identified as antimicrobial stewardship targets. Funding: Duke Global Health Institute
- Open Access
- 8 September 2026
- Published by Springer Nature in Health Economics Review
Economic costs of lower respiratory tract infections among hospitalized patients in southern Sri Lanka: a prospective cohort study
- 8 September 2026
- Published by Springer Nature in Health Economics Review
Open AccessEconomic costs of lower respiratory tract infections among hospitalized patients in southern Sri Lanka: a prospective cohort study
- Open Access
- 18 March 2026
- Published by Springer Nature in Trials
- Vol. 27 (1)
TREATment of Lower Respiratory Tract Infection in Selected Hospitals in Southern Sri Lanka (TREAT-SL): study protocol for a stepped-wedge, cluster-randomized clinical trial
Background: Lower respiratory tract infection (LRTI) is a leading cause of hospitalization and antibacterial use globally. In low- and middle-income countries (LMICs), limited diagnostic resources contribute to inappropriate antibacterial use for LRTI. The aim of this trial is to determine the impact of an electronic clinical decision support tool (eCDST) on LRTI management in Southern Sri Lanka. Methods: This is a prospective, open-label, stepped-wedge, cluster-randomized trial that will be conducted at three public hospitals. A total of 765 patients aged ≥ 14 years who are hospitalized with LRTI will be enrolled across 9 clusters; each cluster consists of a pair of wards (1 male and 1 female). The intervention consists of implementing an eCDST (RespiQuestAB) that physicians use on their mobile phones. RespiQuestAB integrates real-time influenza incidence in Sri Lanka with epidemiological and clinical predictors of LRTI etiology to estimate the probability of the following diagnoses: influenza, other viral (including SARS-CoV-2) infection, bacterial infection, noninfectious condition, or indeterminate. Point-of-care (POC) tests for influenza, SARS-CoV-2, Streptococcus pneumoniae , or procalcitonin are recommended if a positive result increases the probability of the associated diagnosis by at least 5%; clinicians may also order these tests independently. RespiQuestAB provides treatment recommendations regarding antibacterial and antiviral (oseltamivir) use based on the probability of diagnosis. Participants will be followed longitudinally to assess antibacterial prescription and clinical outcomes. The co-primary outcomes are as follows: (1) Duration of antibacterial prescription for the index visit and (2) a composite clinical outcome associated with worsening LRTI by day 30. Secondary outcomes include the individual clinical outcomes of the composite outcome, receipt, and duration of antibacterial and antiviral prescriptions and physician adherence to diagnostic tests and treatments recommended by RespiQuestAB. Exploratory outcomes include Desirability of Outcome Ranking (DOOR) level arranged in an ordinal scale, individual DOOR levels, and prescription of immunomodulatory therapy for SARS-CoV-2. Discussion: Results of this clinical trial will provide information on the impact of the RespiQuestAB on antibacterial use and clinical outcomes among patients with LRTI in an LMIC setting. Trial registration: ClinicalTrials.gov NCT06331364. Registered on March 25, 2024.
- 18 March 2026
- Published by Springer Nature in Trials
- Vol. 27 (1)
Open AccessTREATment of Lower Respiratory Tract Infection in Selected Hospitals in Southern Sri Lanka (TREAT-SL): study protocol for a stepped-wedge, cluster-randomized clinical trial
Background: Lower respiratory tract infection (LRTI) is a leading cause of hospitalization and antibacterial use globally. In low- and middle-income countries (LMICs), limited diagnostic resources contribute to inappropriate antibacterial use for LRTI. The aim of this trial is to determine the impact of an electronic clinical decision support tool (eCDST) on LRTI management in Southern Sri Lanka. Methods: This is a prospective, open-label, stepped-wedge, cluster-randomized trial that will be conducted at three public hospitals. A total of 765 patients aged ≥ 14 years who are hospitalized with LRTI will be enrolled across 9 clusters; each cluster consists of a pair of wards (1 male and 1 female). The intervention consists of implementing an eCDST (RespiQuestAB) that physicians use on their mobile phones. RespiQuestAB integrates real-time influenza incidence in Sri Lanka with epidemiological and clinical predictors of LRTI etiology to estimate the probability of the following diagnoses: influenza, other viral (including SARS-CoV-2) infection, bacterial infection, noninfectious condition, or indeterminate. Point-of-care (POC) tests for influenza, SARS-CoV-2, Streptococcus pneumoniae , or procalcitonin are recommended if a positive result increases the probability of the associated diagnosis by at least 5%; clinicians may also order these tests independently. RespiQuestAB provides treatment recommendations regarding antibacterial and antiviral (oseltamivir) use based on the probability of diagnosis. Participants will be followed longitudinally to assess antibacterial prescription and clinical outcomes. The co-primary outcomes are as follows: (1) Duration of antibacterial prescription for the index visit and (2) a composite clinical outcome associated with worsening LRTI by day 30. Secondary outcomes include the individual clinical outcomes of the composite outcome, receipt, and duration of antibacterial and antiviral prescriptions and physician adherence to diagnostic tests and treatments recommended by RespiQuestAB. Exploratory outcomes include Desirability of Outcome Ranking (DOOR) level arranged in an ordinal scale, individual DOOR levels, and prescription of immunomodulatory therapy for SARS-CoV-2. Discussion: Results of this clinical trial will provide information on the impact of the RespiQuestAB on antibacterial use and clinical outcomes among patients with LRTI in an LMIC setting. Trial registration: ClinicalTrials.gov NCT06331364. Registered on March 25, 2024.
- Open Access
- 20 November 2025
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 5 (1) , e309
Physician knowledge, attitudes, and perceptions of antibiograms: a pre-implementation study in southern Sri Lanka
Objective: The purpose of this study is to explore physicians’ knowledge, attitudes, and perceptions toward antibiograms and identify perceived barriers and facilitators to their implementation in a low-resource setting in Sri Lanka. Design: A qualitative study utilizing semi-structured interviews and thematic analysis. Setting: A public tertiary care hospital in southern Sri Lanka. Participants: Thirty physicians working in pediatric and adult medical wards were purposively sampled and interviewed between June and August 2023. Results: Most physicians had limited prior knowledge or experience with antibiograms. However, after receiving a brief explanation, 29 out of 30 participants expressed strong support for implementing antibiograms, citing potential benefits such as improved antibiotic prescribing, reduced antimicrobial resistance (AMR), and enhanced patient outcomes. Approximately one-third of participants expressed concerns about feasibility due to time constraints, limited laboratory infrastructure, and personnel shortages. Participants recommended delivering antibiogram training through small-group sessions led by a multidisciplinary team. Thematic analysis identified three core themes: (1) limited baseline knowledge of antibiograms, (2) perceived clinical value and enthusiasm for implementation, and (3) barriers related to healthcare system constraints. Conclusions: Physicians in this LMIC setting demonstrated high interest in using antibiograms to guide empiric antibiotic therapy and address AMR. Despite logistical and infrastructural challenges, tailored training and stakeholder engagement may facilitate the successful development and use of antibiograms in similar resource-limited settings.
- 20 November 2025
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 5 (1) , e309
Open AccessPhysician knowledge, attitudes, and perceptions of antibiograms: a pre-implementation study in southern Sri Lanka
Objective: The purpose of this study is to explore physicians’ knowledge, attitudes, and perceptions toward antibiograms and identify perceived barriers and facilitators to their implementation in a low-resource setting in Sri Lanka. Design: A qualitative study utilizing semi-structured interviews and thematic analysis. Setting: A public tertiary care hospital in southern Sri Lanka. Participants: Thirty physicians working in pediatric and adult medical wards were purposively sampled and interviewed between June and August 2023. Results: Most physicians had limited prior knowledge or experience with antibiograms. However, after receiving a brief explanation, 29 out of 30 participants expressed strong support for implementing antibiograms, citing potential benefits such as improved antibiotic prescribing, reduced antimicrobial resistance (AMR), and enhanced patient outcomes. Approximately one-third of participants expressed concerns about feasibility due to time constraints, limited laboratory infrastructure, and personnel shortages. Participants recommended delivering antibiogram training through small-group sessions led by a multidisciplinary team. Thematic analysis identified three core themes: (1) limited baseline knowledge of antibiograms, (2) perceived clinical value and enthusiasm for implementation, and (3) barriers related to healthcare system constraints. Conclusions: Physicians in this LMIC setting demonstrated high interest in using antibiograms to guide empiric antibiotic therapy and address AMR. Despite logistical and infrastructural challenges, tailored training and stakeholder engagement may facilitate the successful development and use of antibiograms in similar resource-limited settings.
- Open Access
- 29 October 2025
- Published by Cambridge University Press (CUP) in Journal of Clinical and Translational Science
- Vol. 9 (1) , 1-30
Host gene expression in the Nasopharynx can discriminate microbiologically confirmed viral and bacterial lower respiratory tract infection
Introduction: Distinguishing viral versus bacterial lower respiratory tract infection (LRTI) is challenging. We previously developed a rapid, host response-based test (Biomeme HR-B/V assay) using peripheral blood samples to identify viral versus bacterial infection. We assessed the performance of this assay when using nasopharyngeal (NP) samples. Methods: Patients with LRTI were enrolled, and a NP swab sample was run using the HR-B/V assay (assessing 24 gene targets) on the Franklin TM platform. The performance of the prior classifier at identifying viral versus bacterial infection was assessed. A novel predictive model was generated for NP samples using the same 24 targets. Results were validated using external datasets with nasal/NP RNA sequence data. Results: Nineteen patients (median age 62 years, 52.1% male) were included. When using the prior HR-B/V classifier on NP samples of 19 patients with LRTI (12 viral, 7 bacterial), the area under the receiver operator curve (AUC) for viral versus bacterial infection was 0.786 (0.524–1), with accuracy 0.79 (95% CI 0.57–0.91), positive percent agreement (PPA) 0.43 (95% CI 0.16–0.75), and negative percent agreement (NPA) 1.00 (95% CI 0.76–1). The novel model had AUC 0.881 (95% CI 0.726–1), accuracy 0.84 (95% CI 0.62–0.94), PPA 0.86 (95% CI 0.49–0.97), and NPA 0.83 (95% CI 0.55–0.95) for bacterial infection. Validation in two external datasets showed AUC of 0.932 (95% CI 0.90–0.96) and 0.915 (95% CI 0.88–0.95). Conclusions: We show that host response in the nasopharynx can distinguish viral versus bacterial LRTI. These findings need to be replicated in larger cohorts with diverse LRTI etiologies.
- 29 October 2025
- Published by Cambridge University Press (CUP) in Journal of Clinical and Translational Science
- Vol. 9 (1) , 1-30
Open AccessHost gene expression in the Nasopharynx can discriminate microbiologically confirmed viral and bacterial lower respiratory tract infection
Introduction: Distinguishing viral versus bacterial lower respiratory tract infection (LRTI) is challenging. We previously developed a rapid, host response-based test (Biomeme HR-B/V assay) using peripheral blood samples to identify viral versus bacterial infection. We assessed the performance of this assay when using nasopharyngeal (NP) samples. Methods: Patients with LRTI were enrolled, and a NP swab sample was run using the HR-B/V assay (assessing 24 gene targets) on the Franklin TM platform. The performance of the prior classifier at identifying viral versus bacterial infection was assessed. A novel predictive model was generated for NP samples using the same 24 targets. Results were validated using external datasets with nasal/NP RNA sequence data. Results: Nineteen patients (median age 62 years, 52.1% male) were included. When using the prior HR-B/V classifier on NP samples of 19 patients with LRTI (12 viral, 7 bacterial), the area under the receiver operator curve (AUC) for viral versus bacterial infection was 0.786 (0.524–1), with accuracy 0.79 (95% CI 0.57–0.91), positive percent agreement (PPA) 0.43 (95% CI 0.16–0.75), and negative percent agreement (NPA) 1.00 (95% CI 0.76–1). The novel model had AUC 0.881 (95% CI 0.726–1), accuracy 0.84 (95% CI 0.62–0.94), PPA 0.86 (95% CI 0.49–0.97), and NPA 0.83 (95% CI 0.55–0.95) for bacterial infection. Validation in two external datasets showed AUC of 0.932 (95% CI 0.90–0.96) and 0.915 (95% CI 0.88–0.95). Conclusions: We show that host response in the nasopharynx can distinguish viral versus bacterial LRTI. These findings need to be replicated in larger cohorts with diverse LRTI etiologies.
- Open Access
- 21 August 2025
- Published by Taylor & Francis in Global Health Action
- Vol. 18 (1) , 2543603
Academic global health collaboration: the Ruhuna-Duke partnership
The role of institutional partnerships is increasingly recognized as a means of advancing our collective efficacy in improving public health. Shared challenges related to infectious and chronic diseases, as well as social determinants of health including environmental stressors, have led to a growth in academic global health collaborations. Triggered by the 2004 tsunami, the University of Ruhuna, Sri Lanka, and Duke University, USA, established an educational and research collaboration that has been sustained and broadened over two decades. The initiation and development of the collaboration, as well as its educational and research components, are described in this manuscript. We discuss lessons learned that may be of interest to other emerging partnerships: the keys to the collaboration's success, challenges and barriers faced, as well as plans to sustain and further grow an equitable, academically rigorous, and impactful global health partnership.
- 21 August 2025
- Published by Taylor & Francis in Global Health Action
- Vol. 18 (1) , 2543603
Open AccessAcademic global health collaboration: the Ruhuna-Duke partnership
The role of institutional partnerships is increasingly recognized as a means of advancing our collective efficacy in improving public health. Shared challenges related to infectious and chronic diseases, as well as social determinants of health including environmental stressors, have led to a growth in academic global health collaborations. Triggered by the 2004 tsunami, the University of Ruhuna, Sri Lanka, and Duke University, USA, established an educational and research collaboration that has been sustained and broadened over two decades. The initiation and development of the collaboration, as well as its educational and research components, are described in this manuscript. We discuss lessons learned that may be of interest to other emerging partnerships: the keys to the collaboration's success, challenges and barriers faced, as well as plans to sustain and further grow an equitable, academically rigorous, and impactful global health partnership.
- Open Access
- 7 May 2025
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 112 (5) , 1168-1174
Electronic Clinical Decision Support Tools to Manage Patients with Lower Respiratory Tract Infection: Clinicians’ Perspectives in Sri Lanka
: In low-resource settings, providers often manage lower respiratory tract infections (LRTIs) without diagnostic tests, which may cause antibacterial overuse. Electronic clinical decision support tools (eCDSTs) can support evidence-based decision-making and judicious use of antibacterials. This study aimed to explore the potential of an eCDST to help providers in Sri Lanka effectively manage LRTI. Semi-structured interviews were conducted with 15 clinicians, including 10 males and five females, with an average of 11.6 years (range: 4–25 years) of clinical practice. The interview guide covered clinicians’ interest in an eCDST to manage LRTI and their feedback regarding the desired features of such a tool. Interviews were audio-recorded, transcribed, and coded for themes related to: interest in an eCDST for LRTI, desired tool capabilities, development concerns, and tool design characteristics. All expressed interest in incorporating eCDSTs into their practice. However, the majority emphasized that clinical judgment must supersede recommendations from an eCDST. Four themes emerged regarding desired tool capabilities: information about the pathogen, treatment recommendations, severity of the LRTI, and monitoring of patient progress. Six themes emerged regarding tool development considerations: validated algorithms, regional specificity, seasonality, inclusion of patient’s risk factors, scalability, and the importance of updated and locally relevant recommendations. Participants stressed that the tool design should be simple, timesaving, and internet-independent. Electronic clinical decision support tools are capable of improving patient care and reduce antibiotic overuse, which may impact downstream antibacterial resistance. Future research should develop an eCDST for LRTI with local input and evaluate its impact on appropriate antibacterial use and patient outcomes.
- 7 May 2025
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 112 (5) , 1168-1174
Open AccessElectronic Clinical Decision Support Tools to Manage Patients with Lower Respiratory Tract Infection: Clinicians’ Perspectives in Sri Lanka
: In low-resource settings, providers often manage lower respiratory tract infections (LRTIs) without diagnostic tests, which may cause antibacterial overuse. Electronic clinical decision support tools (eCDSTs) can support evidence-based decision-making and judicious use of antibacterials. This study aimed to explore the potential of an eCDST to help providers in Sri Lanka effectively manage LRTI. Semi-structured interviews were conducted with 15 clinicians, including 10 males and five females, with an average of 11.6 years (range: 4–25 years) of clinical practice. The interview guide covered clinicians’ interest in an eCDST to manage LRTI and their feedback regarding the desired features of such a tool. Interviews were audio-recorded, transcribed, and coded for themes related to: interest in an eCDST for LRTI, desired tool capabilities, development concerns, and tool design characteristics. All expressed interest in incorporating eCDSTs into their practice. However, the majority emphasized that clinical judgment must supersede recommendations from an eCDST. Four themes emerged regarding desired tool capabilities: information about the pathogen, treatment recommendations, severity of the LRTI, and monitoring of patient progress. Six themes emerged regarding tool development considerations: validated algorithms, regional specificity, seasonality, inclusion of patient’s risk factors, scalability, and the importance of updated and locally relevant recommendations. Participants stressed that the tool design should be simple, timesaving, and internet-independent. Electronic clinical decision support tools are capable of improving patient care and reduce antibiotic overuse, which may impact downstream antibacterial resistance. Future research should develop an eCDST for LRTI with local input and evaluate its impact on appropriate antibacterial use and patient outcomes.
- Open Access
- 23 April 2025
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 5 (4) , e0004358
Exploring supportive roles for global north investigators in global health research
Many academics are increasingly pushing for solutions to address inequitable partnership dynamics in global health research and practice. Efforts to improve equity in collaborations have prompted academic institutions to grapple with promotion and tenure criteria (usually Global North institutions), as these criteria often require leadership on grants, publications, and conference presentations for advancement. From inequitable funding opportunities to the invisibilization of Global South researchers, these components are rooted in normalizing and upholding unequal power dynamics. Therefore, the purpose of this project was to explore ways in which Global North academic institutions can value supportive roles taken by their investigators in global health research. A special session was held at the 2022, Consortium of Universities for Global Health (CUGH) meeting, entitled “Incorporating Anti-Racism, Anti-Colonialism, and Anti-Oppression Efforts into Faculty Promotion.” The purpose of the workshop was to assess current practices that participants’ institutions incorporated in promoting anti-racist, anti-colonialist, and anti-oppression efforts within their faculty promotion practices as well as to brainstorm future solutions. A qualitative analysis of the discussion transcripts yielded several themes, including (1) making structural changes to the promotion process, (2) incorporating anti-racism/anti-colonialism perspectives into promotion packets, (3) recalibrating agenda setting and collaboration in Global North-South partnerships, (4) assuring strong mentorship for assembly of the promotion packet, and (5) developing effective capacity strengthening efforts. Given these results, we call upon the global health academic community to implement these suggestions in their policies and practices.
- 23 April 2025
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 5 (4) , e0004358
Open AccessExploring supportive roles for global north investigators in global health research
Many academics are increasingly pushing for solutions to address inequitable partnership dynamics in global health research and practice. Efforts to improve equity in collaborations have prompted academic institutions to grapple with promotion and tenure criteria (usually Global North institutions), as these criteria often require leadership on grants, publications, and conference presentations for advancement. From inequitable funding opportunities to the invisibilization of Global South researchers, these components are rooted in normalizing and upholding unequal power dynamics. Therefore, the purpose of this project was to explore ways in which Global North academic institutions can value supportive roles taken by their investigators in global health research. A special session was held at the 2022, Consortium of Universities for Global Health (CUGH) meeting, entitled “Incorporating Anti-Racism, Anti-Colonialism, and Anti-Oppression Efforts into Faculty Promotion.” The purpose of the workshop was to assess current practices that participants’ institutions incorporated in promoting anti-racist, anti-colonialist, and anti-oppression efforts within their faculty promotion practices as well as to brainstorm future solutions. A qualitative analysis of the discussion transcripts yielded several themes, including (1) making structural changes to the promotion process, (2) incorporating anti-racism/anti-colonialism perspectives into promotion packets, (3) recalibrating agenda setting and collaboration in Global North-South partnerships, (4) assuring strong mentorship for assembly of the promotion packet, and (5) developing effective capacity strengthening efforts. Given these results, we call upon the global health academic community to implement these suggestions in their policies and practices.
- Open Access
- 11 December 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (1) , ofae729
A Rapid Host Response Blood Test for Bacterial/Viral Infection Discrimination Using a Portable Molecular Diagnostic Platform
Background: Difficulty discriminating bacterial versus viral etiologies of infection drives unwarranted antibacterial prescriptions and, therefore, antibacterial resistance. Methods: Utilizing a rapid portable test that measures peripheral blood host gene expression to discriminate bacterial and viral etiologies of infection (the HR-B/V assay on Biomeme's polymerase chain reaction–based Franklin platform), we tested 3 cohorts of subjects with suspected infection: the HR-B/V training cohort, the HR-B/V technical correlation cohort, and a coronavirus disease 2019 cohort. Results: The Biomeme HR-B/V test showed very good performance at discriminating bacterial and viral infections, with a bacterial model accuracy of 84.5% (95% confidence interval [CI], 80.8%–87.5%), positive percent agreement (PPA) of 88.5% (95% CI, 81.3%–93.2%), negative percent agreement (NPA) of 83.1% (95% CI, 78.7%–86.7%), positive predictive value of 64.1% (95% CI, 56.3%–71.2%), and negative predictive value of 95.5% (95% CI, 92.4%–97.3%). The test showed excellent agreement with a previously developed BioFire HR-B/V test, with 100% (95% CI, 85.7%–100.0%) PPA and 94.9% (95% CI, 86.1%–98.3%) NPA for bacterial infection, and 100% (95% CI, 93.9%–100.0%) PPA and 100% (95% CI, 85.7%–100.0%) NPA for viral infection. Among subjects with acute severe acute respiratory syndrome coronavirus 2 infection of ≤7 days, accuracy was 93.3% (95% CI, 78.7%–98.2%) for 30 outpatients and 75.9% (95% CI, 57.9%–87.8%) for 29 inpatients. Conclusions: The Biomeme HR-B/V test is a rapid, portable test with high performance at identifying patients unlikely to have bacterial infection, offering a promising antibiotic stewardship strategy that could be deployed as a portable, laboratory-based test.
- 11 December 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (1) , ofae729
Open AccessA Rapid Host Response Blood Test for Bacterial/Viral Infection Discrimination Using a Portable Molecular Diagnostic Platform
Background: Difficulty discriminating bacterial versus viral etiologies of infection drives unwarranted antibacterial prescriptions and, therefore, antibacterial resistance. Methods: Utilizing a rapid portable test that measures peripheral blood host gene expression to discriminate bacterial and viral etiologies of infection (the HR-B/V assay on Biomeme's polymerase chain reaction–based Franklin platform), we tested 3 cohorts of subjects with suspected infection: the HR-B/V training cohort, the HR-B/V technical correlation cohort, and a coronavirus disease 2019 cohort. Results: The Biomeme HR-B/V test showed very good performance at discriminating bacterial and viral infections, with a bacterial model accuracy of 84.5% (95% confidence interval [CI], 80.8%–87.5%), positive percent agreement (PPA) of 88.5% (95% CI, 81.3%–93.2%), negative percent agreement (NPA) of 83.1% (95% CI, 78.7%–86.7%), positive predictive value of 64.1% (95% CI, 56.3%–71.2%), and negative predictive value of 95.5% (95% CI, 92.4%–97.3%). The test showed excellent agreement with a previously developed BioFire HR-B/V test, with 100% (95% CI, 85.7%–100.0%) PPA and 94.9% (95% CI, 86.1%–98.3%) NPA for bacterial infection, and 100% (95% CI, 93.9%–100.0%) PPA and 100% (95% CI, 85.7%–100.0%) NPA for viral infection. Among subjects with acute severe acute respiratory syndrome coronavirus 2 infection of ≤7 days, accuracy was 93.3% (95% CI, 78.7%–98.2%) for 30 outpatients and 75.9% (95% CI, 57.9%–87.8%) for 29 inpatients. Conclusions: The Biomeme HR-B/V test is a rapid, portable test with high performance at identifying patients unlikely to have bacterial infection, offering a promising antibiotic stewardship strategy that could be deployed as a portable, laboratory-based test.